Kevin Davidson President & CEO

1. Kevin Davidson President & CEO

2. Company is at major inflection point driven by new product based revenue opportunity Products address $1.5 billion US market for collection and disposal of operating room generated patient fluid waste Launch of the Streamway™ System now underway Razor/Razor blade business model for hospital/surgery centers First systems installed and order pipeline building New funding to expand manufacturing to meet order demand Competitive advantages to major industry approaches Automation; Efficiency; Costs New public listing: BIOR.OB Company Highlights

3. Existing Disposal Process Start End End

4. Operative Fluid Management The issues… • Safety • Cost • OR Efficiency • Regulatory Compliance • Environment

5. Fully automated, continuous suction system Infinite fluid processing Processes all fluids, tissue and bone chips Visibility & measurement Wall mount frees up OR floor space Rapid OR turnaround time with self-contained disposables and automated cleaning > 60% gross margins with volume The STREAMWAY™ System Patented Instrument

6. Kits contain filter cartridge and cleaning fluids Filter used to keep instrument clear of debris Fluid cleans unit after each use Removes all bacteria Prevents formation of bio-films which can host viruses Prevents cross-contamination Biodegradable ~ 70% gross margins at volume The STREAMWAY™ System Single-Use Disposable Kit

7. STREAMWAYTM Disposal Process Patented, closed, automated, continuous, wall mounted system that provides unlimited disposal, measurement, and visibility of operative fluids.

8. Patented Instrument United States market has in excess of 40,000(1)ORs and surgical centers 5% to 8% annual growth of new facilities(2) Market opportunity exceeds $650 million Disposable Kit United States has approx. 50,000,000 hospital and ambulatory surgical procedures annually Market opportunity exceeds $850 million U.S. Market Opportunity Total US Only market opportunity > $1,500,000,000 • All data from AHA Hospital Statistics, 2008 edition • AIA Consensus Construction Forecast

9. Competitive Overview STREAMWAY System is “the” superior solution to operative fluid management • Ultimate in compliance • Green solution • Space & workflow efficiencies Continuous flow Fully automated Cost effectiveness

10. BioDrain vs. The Canister Cost Per OR - Per Year Solidifier Pouring BioDrain(1) (1)In addition, BioDrain creates OR efficiencies that could add significant revenue! WE IMPROVE HOSPITALS’ FINANCIALS!

11. Operative Fluid ManagementRegulatory Drivers • Enables hospital compliance to state and federal regulations • OSHA, EPA, DOT, CDC • Reduces cost of infecting hospital staff • No requirement for a specialized handling/transportation department or hazardous materials compliance • FDA 510(K) clearance received

12. Marketing and Distribution Plan • Operations • Function headed by experienced industry VP of Sales • Currently utilizing experienced independent sales reps • Plan to supplement with direct/regional managers • Customer strategy • Pursuing VA, government, IDN, large hospital chains, surgery centers • OR Manager, Infection Control, Finance Managers – Key target customers • Future expansion • In conversations with large companies re: distribution partnerships. • CE Mark & independent distributors planned for ROW

13. Sales Pipeline – Potential Supporting revenue forecast • Indiana Regional Hospital 20 Units • Chicago Hospital 26 • North Dakota Medcenter 10 • Minneapolis Hospital 10 • Wisconsin Clinic 28 • Minneapolis Hospital 14 • L.A. Sports/Ortho Center 4 • Minneapolis Suburb Medical Center 8

14. Sales Pipeline - Potential • Indiana Teaching Hospital 28 Units • Illinois Flagship Hospital 15 • Midwest University Hospital 10 • Midwest University Hospital 15 • Wisconsin Hospital 7 • Dallas Hospital 4

15. Operations Outsourcing is Key – leveraging internal resources/containing costs Machine production – partner with Trivirix – FDA approved med tech manufacturer Fluid production – partner with Oculus Innovative Sciences – FDA approved fluid provider Installation / Service – partner with Belimed – FDA approved manufacturer and servicer of hospital based infection control & sterilization products Utilize independent sales reps, regulatory and other consultants. Maintain control/tap in to other organizations/keep expenses down.

16. Short Term Milestones Secure patent - done Produce production-ready units - done Complete UL/TUV testing - done Submit FDA 510K - done FDA approval – done Product launch – done Beta site installations – done Pass FDA audit - done Complete SEC registration – done Trading on OTCBB - done Establish distribution channel –16 states covered Secure additional financing –Raising funds now

17. BioDrain Financial Forecast ($000) 2010 2012 2013 2014 2011 Sales 2,066 11,145 Hardware 16,440 22,215 28,425 1,390 Disposables Service 7,841 21,082 39,636 63,943 Total 32 3,488 169 19,155 331 37,852 461 62,312 601 92,969 Gross Profit 1,753 11,410 24,488 43,176 65,141 Operating Income 1,967 10,121 38,491 (1,738) 23,293 (1,738) Net Income - After Tax 1,180 6,072 23,094 13,976

18. Management Kevin Davidson, President & CEO, Director Mr. Davidson has over 20 years experience in the medical technology sector. He has been the CFO of three medical technology companies and as an investment banker led and closed several transactions in this sector. Chad Ruwe, COO, Director Mr. Ruwe has over 20 years experience in critical fluid management industries focused on containment, management, and delivery of highly toxic and corrosive fluids. Mr. Ruwe has extensive experience managing international joint ventures, wholly owned foreign entities and outsource manufacturing partners. Jess Carsello, VP of Sales & Marketing Mr. Carsello has a long history of medical sales and management successes, he has been a senior-level sales executive in medical device companies spending most of his selling in the OR setting. He has managed sales forces nationally for many years. Alan Shuler, Acting CFO Mr. Shuler has over 30 years of financial experience. Mr. Shuler has been the CFO of publically traded companies, is SEC knowledgeable, provides Investor Relations expertise, and has lead and completed several funding efforts with several different entities.

19. Board of Directors Larry Gadbaw Served as BioDrain President and CEO and Executive VP Business Development ● President and COO and Director of Augustine Medical, Inc. ● President, CEO, Treasurer and Director of Bio-Vascular, Inc. Dr. Peter Morawetz Director of BioDrain since inception ● Consulting experience with notable corporation including: Medtronic, EMPI, Hutchinson Technologies, Minntech, Bauer Biopsy Needles, American Medical, Lectec and Walker Reading Technologies Tom McGoldrick CEO of Monteris Medical Inc. ● CEO of Fastitch Surgical ● President and CEO of Minntech ● Senior marketing, business development and international positions at Medtronic, Cardiac Pacemakers, Inc. and Johnson & Johnson Andy Reding President and CEO of TRUMPF Medical Systems, Inc. ● National sales leader Smith & Nephew Endoscopy ● Sales, marketing, and management, Berchtold Corporation ● Significant experience marketing products for the OR, ER and ICU Jim Dauwalter Former CEO and Chairman of Entegris, Inc., with broad functional background and experience including sales & marketing, operational, and financial experiences.

20. Key Points for Investment • Streamway System: Provides “Green” solution • System completed and launched; scale-up & manufacturing ready • Addresses real customer needs – safety, automation and cost reduction • Product: differentiable & provides for regulatory compliance • Business model: razor / razor blade • Market established, large and growing • Intellectual Property: strong and secured • Management: experienced, proven, liquidity events • Funding to drive manufacturing and market expansion • New public listing with attractive valuation

21. Capitalization Overview > $ 3.0 Million invested to date Approximately 12 million shares outstanding Approximately 23 million shares fully diluted Most recent round at $.50 per unit (1 share plus 1 $0.65 warrant) No institution / corporate funding to date One class of common stock – no preferred

22. Join the New Movement • Safer • Less Costly • More Efficient • Regulatory Compliant • Environmentally Friendly